Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells

References

• Rogers, M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Design. 2003, 32, 2643–2658.
   Google Scholar
• Delmas, P.D. Treatment of postmenopausal osteoporosis. Lancet 2002, 359 (9322), 2018–2026.
   PubMed Web of Science ®Google Scholar
• Roux, C., Dougados, M. Treatment of patients with Paget’s disease of bone. Drugs 1999, 58 (5), 823–830.
   Google Scholar
• Coleman, R.E. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer. Treat. Rev. 2001, 27 (3), 165–176.
   Google Scholar
• Rogers, M.J. From molds and macrophages to mevalonate: A decade of progress in understanding the molecular mode of action of bisphosphonates. Calcified. Tissue. Int. 2004, 75 (6), 451–461.
   Google Scholar
• Dunford, J.E., Thompson, K., Coxon, F.P., Luckman, S.P., Hahn, F.M., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 2001, 296 (2), 235–242.
   PubMed Web of Science ®Google Scholar
• Amin, D., Cornell, S.A., Gustafson, S.K., Needle, S.J., Ullrich, J.W., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 1992, 33 (11), 1657–1663.
   Google Scholar
• Luckman, S.P., Hughes, D.E., Coxon, F.P., Graham, R., Russell, G., et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. 1998, 13 (4), 581–589.
   PubMed Web of Science ®Google Scholar
• Widler, L., Jaeggi, K.A., Glatt, M., Müller, K., Bachmann, R., et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. 2002, 45 (17), 3721–3738.
   Google Scholar
• Durie, B.G., Katz, M., Crowley, J. Osteonecrosis of the jaw and bisphosphonates. New Engl. J. Med. 2005, 353 (1), 99–102.
   Google Scholar
• Banchereau, J., Steinman, R.M. Dendritic cells and the control of immunity. Nature 1998, 392 (6673), 245–252.
   PubMed Web of Science ®Google Scholar
• Jonuleit, H., Kuhn, U., Muller, G., Steinbrink, K., Paragnik, L., et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 1997, 27(12), 3135–3142.
   PubMedGoogle Scholar
• Kato, T., Yamane, H., Nariuchi, H.. Differential effects of LPS and CD40 ligand stimulations on the induction of IL-12 production by dendritic cells and macrophages. Cell Immunol. 1997, 181 (1), 59–67.
   Google Scholar
• Cella, M., Scheidegger, D., Palmer-Lehmann, K., Lane, P., Lanzavecchia, A., et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 1996, 184 (2), 747–752.
   Google Scholar
• Labeur, M.S., Roters, B., Pers, B., Mehling, A., Luger, T.A., et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 1999, 162 (1), 168–175.
   Google Scholar
• Moreau, M.F., Guillet, C., Massin, P., Chevalier, S., Gascan, H., et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem. Pharmacol. 2007, 73 (5), 718–723.
   Google Scholar
• Dieli, F., Gebbia, N., Poccia, F., Caccamo, N., Montesano, C.,et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102 (6), 2310–2311.
   Google Scholar
• Fiore, F., Castella, B., Nuschak, B., Bertieri, R., Mariani, S., et al. Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. Blood 2007, 110 (3), 921–927.
   PubMed Web of Science ®Google Scholar
• Takahara, M., Miyai, M., Tomiyama, M., Mutou, M., Nicol, A.J., et al. Copulsing tumor antigen-pulsed dendritic cells with zoledronate efficiently enhance the expansion of tumor antigen-specific CD8+ T cells via Vgamma9gammadelta T cell activation. J. Leukoc. Biol. 2008, 83(3), 742–754.
   Google Scholar
• Pedersen, A.E., Thorn, M., Gad, M., Walter, M.R., Johnsen, H.E., et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand. J. Immunol. 2005, 61 (2), 147–156.
   Google Scholar
• Colic, M., Mojsilovic, S., Pavlovic, B., Vucićević, D., Majstorović, I., et al. Comparison of two different protocols for the induction of maturation of human dendritic cells in vitro. Vojnosanit. Pregl. 2004, 61 (5), 471–478.
   Google Scholar
• Zhang, M., Tang, H., Guo, Z., An, H., Zhu, X., et al. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat. Immunol. 2004, 5 (11), 1124–1133.
   Google Scholar
• Piemonti, L., Monti, P., Allavena, P., Sironi, M., Soldini, L., et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 1999, 162 (11), 6473–6481.
   Google Scholar
• Lee, J.J., Liao, H.F., Yang, Y.C., Liu, C.L., Chen, Y.Y., et al. Platonin modulates differentiation and maturation of human monocyte-derived dendritic cells. Int. Immunopharmacol. 2006, 6 (2), 287–293.
   Google Scholar
• Linsley, P.S., Brady, W., Urnes, M., Grosmaire, L.S., Damle, N.K., et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991a, 174 (3), 561–569.
   Google Scholar
• Linsley, P.S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N.K., et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. 1991b, 173 (3), 721–730.
   Google Scholar
• Doyle, A.M., Mullen, A.C., Villarino, A.V., Hutchins, A.S., High, F.A., et al. Induction of cytotoxic T lymphocyte antigen 4 (CTLA-4) restricts clonal expansion of helper T cells. J. Exp. Med. 2001, 194 (7), 893–902.
   Google Scholar
• Fallarino, F., Fields, P.E., Gajewski, T.F. B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28. J. Exp. Med. 1998, 188 (1), 205–210.
   Google Scholar
• Sansom, D.M., Manzotti, C.N., Zheng, Y. What’s the difference between CD80 and CD86? Trends Immunol. 2003, 24 (6), 314–319.
   Google Scholar
• Parlato, S., Santini, S.M., Lapenta, C., Di Pucchio, T., Logozzi, M., Giammarioli, A.M., Malorni, W., Fais, S., Belardelli, F. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood. 2001, 15, 98 (10), 3022–3029.
   Google Scholar
• Kellinsalmi, M., Monkkonen, H., Monkkonen, J., Leskelä, H.V., Parikka, V., et al. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin. Pharma. Toxicol. 2005, 97 (6), 382–391.
   Google Scholar
• Chen, T., Berenson, J., Vescio, R., Swift, R., Gilchick, A., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J. Clin. Pharmacol. 2002, 42 (11), 1228–1236.
   PubMed Web of Science ®Google Scholar
• Woo, S.B., Hellstein, J.W., Kalmar, J.R. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. 2006, 144 (10), 753–761.
   PubMed Web of Science ®Google Scholar
• Vincenzi, B., Santini, D., Dicuonzo, G., Battistoni, F., Gavasci, M., et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J. Interf. Cytok. Res. 2005, 25 (3), 144–151.
   Google Scholar
• Bringmann, A., Schmidt, S.M., Weck, M.M., Brauer, K.M., von Schwarzenberg, K., et al. Zoledronic acid inhibits the function of Toll-like receptor 4 ligand activated monocyte-derived dendritic cells. Leukemia 2007, 21 (4), 732–738.
   Google Scholar
• Coxon, F.P., Helfrich, M.H., Van’t Hof, R., Sebti, S., Ralston, S.H., et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J. Bone. Miner. Res. 2000, 15 (8), 1467–1476.
   Google Scholar
• Suri, S., Mönkkönen, J., Taskinen, M., Pesonen, J., Blank, M.A., et al. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001, 29 (4), 336–343.
   Google Scholar
• Coxon, J.P., Oades, G.M., Kirby, R.S., Colston, K.W. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. B.J.U. Int. 2004, 94 (1), 164–170.
   Google Scholar